Another victory against #Melanoma: news.bms.com/news/corporate…

Our findings establish the LAG-3 pathway as the 3rd immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. bit.ly/2RvQCchvia @ascopost

Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced #Melanoma onclive.com/view/relatlima…

Making progress against #Melanoma #ASCO youtu.be/BUuyGzCOXEU

Lazy Sunday

Great to be back at the Melanoma Research scientific retreat with friends from around the world including Jason Luke, MD, FACP

Sine 2013, my Johns Hopkins Medicine team and I have led development of a new #Immunotherapy, which was approved today by FDA for advanced #Melanoma onclive.com/view/fda-appro… via @onclive

Oncology milestone in #melanoma w U.S. FDA approval of anti-LAG3 relatlimab. The 3rd checkpoint! Congrats Hussein Tawbi, MD, PhD Evan Lipson Steve Hodi & Professor Georgina Long AO bringing this forward. Triplet IO w CTLA4 in mel vs PD1+LAG3 +TKI/chemo & for other cancers? onclive.com/view/fda-appro…

Congratulations to Dr. Kara Schenk for earning received a 2022 Conquer Cancer, the ASCO Foundation – Endowed Merit Award in honor of Dr. Cecil "Pete" Coggins. Dr. Schenk received this award for earning the highest score for her abstract focused on melanoma. We're so proud of you, Dr. Schenk!

Kara Schenk presenting a VERY cool study for nivo+tacrolimus+prednisone -+/- ipi in kidney transplant recipients with cutaneous cancers. This is a key question for skin cancer with implications for many other diseases. Evan Lipson #melanoma #ASCO22 OncoAlert

Wonderful to see #KaraSchenk & Evan Lipson’s trial on the use ICIs in patients with renal transplants and cancer! So exciting! Results with nivo/ipi markedly improved from single agent nivo! More to come! NCI CTEP Clinical Research National Cancer Institute NCI Treatment HopkinsHemOncFellowship Johns Hopkins Kimmel Cancer Center

Great to be at #ASCO2022 & reviewing data for #melanoma pts: short-course braf+mek does not appear to enhance pd1 activity on neoadjuvant platform (Melanoma Institute Australia NeoTrio trial); pembrolizumab decreases the risk of DMFS c/f placebo (Keynote 716); pathCR rate 55% desmoplastic mel.

#ASCO2022 was spectacular :) Saw friends, talked science, and Dr. Kara Schenk presented data from our trial testing nivo+tacro+pred +/- ipi in kidney #transplant recipients with #skin #Cancer. #Melanoma

.Dawn Flythe Moore, Jamie, Mia, and I loved having the Easter Bunny here at Government House for this year’s annual Easter Egg Roll, but Tucker was the most excited of all! 🐶🐰

This upcoming Thursday, Dr Neil Love will be joined by clinical investigators to discuss the latest data sets in melanoma and nonmelanoma skin cancers. Register at the link below. bit.ly/3CZG2yi

Our trial investigated how immunotherapy can help organ #transplant recipients fight #skincancer and keep their transplanted organs safe. Elad Sharon @headneckmd ascopubs.org/doi/10.1200/JC…

Hey #oncology RN friends! We're looking for a nurse care coordinator to join our team at Hopkins. Check out the posting... jobs.hopkinsmedicine.org/job/rn-registe…

Optimizing care for patients with #melanoma: answersincme.com/AUY #GetYourAnswersInCME #AiCME

The Society for Immunotherapy of Cancer NMSC CPG rapid update v1.1 includes new/revised clinical recommendations pertaining to additional anti-PD-1 therapies for patients with CSCC and MCC. More information: sitcancer.org/NMSC-guideline #SITCGuidelines #NMSC #CSCC #MCC #Immunotherapy